Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1188529 | 0.79 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL31258279 | 0.79 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL258502 | 0.79 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL541710 | 0.79 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL15845273 | 0.77 | TSHR (0.45) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL9326405 | 0.75 | TSHR (0.43) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL8647690 | 0.74 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL29357701 | 0.73 | TSHR (0.53) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL3127305 | 0.73 | TSHR (0.53) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL4480 | 0.73 | TSHR (0.53) | TSHRACHEALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181359-B2 | Method of production of ethylene-based polymer particles and stretch-molded article obtained from ethylene-based polymer particles | MITSUI CHEMICALS, INC. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2631252-B1 | METHOD FOR PRODUCING ETHYLENE-BASED POLYMER PARTICLES, AND STRETCH-MOLDED ARTICLE OBTAINED FROM ETHYLENE-BASED POLYMER PARTICLES | MITSUI CHEMICALS INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-2631252-A1 | METHOD FOR PRODUCING ETHYLENE-BASED POLYMER PARTICLES, AND STRETCH-MOLDED ARTICLE OBTAINED FROM ETHYLENE-BASED POLYMER PARTICLES | Mitsui Chemicals, Inc. (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-20130209805-A1 | METHOD OF PRODUCTION OF ETHYLENE-BASED POLYMER PARTICLES AND STRETCH-MOLDED ARTICLE OBTAINED FROM THE ETHYLENE-BASED POLYMER PARTICLES | MITSUI CHEMICALS, INC (JP) | 2013-08-15 | — | — | US | disclosed |
| US-7888330-B2 | Phosphoramidate derivatives of FAU | WAYNE STATE UNIVERSITY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20080292553-A1 | Phosphoramidate Derivatives of Fau | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-11-27 | — | — | US | disclosed |
| WO-2007056596-A2 | PHOSPHORAMIDATE DERIVATIVES OF FAU | WAYNE STATE UNIVERSITY (US) | 2007-05-18 | — | — | WO | disclosed |
| US-6897176-B2 | Olefin polymerization catalyst and process for producing olefin polymer with the catalyst | MITSUI CHEMICALS, INC. (JP) | 2005-05-24 | — | — | US | disclosed |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1417967-A1 | NOVEL VIRUS PROLIFERATION INHIBITION/VIRUCIDAL METHOD AND NOVEL PYRADINE NUCLEOTIDE/PYRADINE NUCLEOSIDE ANALOGUE | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-20020169072-A1 | Olefin polymerization catalyst and process for produing Olefin polymer with the catalyst | MITSUI CHEMICALS, INC. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-1238989-A2 | Olefin polymerization catalyst and process for producing olefin polymer with the catalyst | Mitsui Chemicals, Inc. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292553-A1 | Phosphoramidate Derivatives of Fau | DUT, FAU, DPYD | TSHR 3891/4885ACHE 4698/4885ALDH1A1 2258/4885 |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | CDK5, NT5C3B, CDK15 | TSHR 2112/4885ACHE 4037/4885ALDH1A1 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.